Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

PPPR15A, a stress response gene is upregulated in malignant myeloid progenitors in AML and higher risk MDS.

Agni Vitsioti, Konstantinos Theodorakopoulos, Anastasia Apostolidou, Anthi Bouchla, Christina Sotiropoulou, Christina Apostolopoulou, Thomas Thomopoulos, Pinelopi Vrytia, Artemis Zorba, Theodora Chatziligeroudi, Ioulia Markaki, Georgia Karamanou, Sotiris Papageorgiou, Eleni Katsantoni, Vassiliki Pappa

Blood (2025) 146 (Supplement 1): 6771.

https://doi.org/10.1182/blood-2025-6771

Published: 2025

Journal Articles

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study

Christina Sotiropoulou, Christos Kontos, Anthi Bouchla, Theodora Chatziligeroudi, Sotiris Papageorgiou, Agni Vitsioti, Christina Apostolopoulou, Ioulia Markaki, Georgia Karamanou, Theodoros Karantanos, Vassiliki Pappa

Blood (2025) 146 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2025-6799

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

The Prognostic Significance of Serum β 2 - Microglobulin Levels (sβ 2 m) in Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 6476.

https://doi.org/10.1182/blood-2024-210185

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Disease Bulk and/or Very High LDH As Adverse Factors in IPI 1-2 Diffuse Large B-Cell Lymphoma (DLBCL): A Hellenic Database Validation of the LEO Cohort

Theodoros P. Vassilakopoulos, Maria Panagiota Arapaki, Christina Apostolopoulou, Evgenia Verrou, Christina H. Kalpadakis, Alexia Piperidou, Athanasios Liaskas, Sotirios Sachanas, Theodora Triantafyllou, Aikaterini Bitsani, Maria Dimou, Maria Anastasia Ioakeim, Marina Siakantaris, Gerassimos Pangalis, Eirini Katodritou, Maria Angelopoulou, Panayiotis Panayiotidis, Vassiliki Pappa, Sotirios G. Papageorgiou

Blood (2024) 144 (Supplement 1): 6362.

https://doi.org/10.1182/blood-2024-210585

Published: 2024

Journal Articles

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Christina-Nefeli Kontandreopoulou, Stavroula Syriopoulou, Panagiotis T Diamantopoulos, Nefeli Giannakopoulou, Dimitra Vlachopoulou, Panagiota Katsiampoura, Christos Stafylidis, Maria Dimou, Athanasios Galanopoulos, Sotirios Papageorgiou, Eleftheria Hatzimichael, Vassiliki Pappa, Kotsianidis Ioannis, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou

Blood (2022) 140 (Supplement 1): 6958–6959.

https://doi.org/10.1182/blood-2022-165870

Published: 2022

Journal Articles

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Anthi Bouchla, Theodoros Loupis, Georgia Delikonstantinos, Frieda Kontsioti, Vassiliki Mpakou, Maria Dellatola, Maria Pagoni, Konstantinos Theodorakopoulos, Sotirios Papageorgiou, Argiris Symeonidis, Vassiliki Pappa

Blood (2022) 140 (Supplement 1): 6250–6251.

https://doi.org/10.1182/blood-2022-158980

Published: 2022

Journal Articles

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Blood (2021) 138 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2021-149630

Published: 2021

Journal Articles

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136940

Published: 2020

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD

Blood (2019) 134 (Supplement_1): 5417.

https://doi.org/10.1182/blood-2019-131003

Published: 2019

Journal Articles

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

Eleftheria Lamprianidou, Chrysoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, PhD, Anastasia Filia, Stamatia Laidou, Theodoros P. Vassilakopoulos, MD PhD, Sotirios Papageorgiou, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Nora-Athina Viniou, MD PhD, Evangelia Nakou, Anastasia Hadzidimitriou, PhD, George Kassiotis, Elli Papaemmanuil, PhD, Ioannis Mitroulis, Ioannis Kotsianidis

Blood (2019) 134 (Supplement_1): 2988.

https://doi.org/10.1182/blood-2019-126504

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Panagiotis T Diamantopoulos, MD PhD, Vassiliki Pappa, MD, Nora-Athina Viniou, MD PhD, Ioannis Kotsianidis, Alexandra Kourakli, MD PhD, Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Elena E. Solomou, MD, Anastasia Pouli, MD PhD, Panagiotis Panagiotidis, MD PhD, Maria Dimou, MD PhD, Kalliopi Zafeiropoulou, Stamatis J. Karakatsanis, MD MSc, Anna Vardi, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Tsokanas, George Drakos, Spyros Hontropoulos, Eleftheria Hatzimichael, Aikaterini Megalakaki, Panagiotis Repousis, MD, Maria Kotsopoulou, Georgia Kaiafa, MD, Menelaos Konstantinos Papoutselis, Anastasia Sioni, Nikolaos Charchalakis, PhD, Eleni Bouronikou, Georgios Vasilopoulos, Vasileios Lazaris, Maria Spiliotopoulou, Flora Kontopidou, Christos K. Kontos, PhD, Stamatina Kalyva, Apostolos Hatzitolios, Helen A. Papadaki, MD PhD, Achilles Anagnostopoulos, Nikolaos Anagnostopoulos, Athanasios Galanopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5427.

https://doi.org/10.1182/blood-2019-127417

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

PPPR15A, a stress response gene is upregulated in malignant myeloid progenitors in AML and higher risk MDS.

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

The Prognostic Significance of Serum β 2 - Microglobulin Levels (sβ 2 m) in Diffuse Large B-Cell Lymphoma (DLBCL)

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Disease Bulk and/or Very High LDH As Adverse Factors in IPI 1-2 Diffuse Large B-Cell Lymphoma (DLBCL): A Hellenic Database Validation of the LEO Cohort

Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification

Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP)

Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Modulation of the IL-6/STAT3 Signaling Axis in CD4 + T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only